Pulmatrix (PULM) Non-Current Deferred Tax Liability (2015 - 2016)

Pulmatrix (PULM) posted Non-Current Deferred Tax Liability of $3.0 million for Q1 2016, little changed sequentially from $3.0 million in Q4 2015.

Pulmatrix (PULM) Non-Current Deferred Tax Liability (2015 - 2016) Analysis & Trends

Pulmatrix has reported Non-Current Deferred Tax Liability for 2 years, with the latest figure at $3.0 million in Q1 2016.

Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $3.0 million in Q1 2016, while the trailing twelve-month figure through Mar 2016 was $3.0 million (changed N/A YoY) and the FY2015 annual result came in at $3.0 million, changed N/A from the prior year.
Non-Current Deferred Tax Liability steadied at $3.0 million in Q1 2016 per PULM's latest filing, from $3.0 million in the prior quarter.
Over five years, Non-Current Deferred Tax Liability peaked at $3.0 million in Q2 2015 and troughed at $3.0 million in Q2 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Pulmatrix	5.46 Mn	5.46 Mn	-

Download Data